• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清非靶向代谢组学描绘了不同非酒精性脂肪性肝病亚型的代谢状态。

Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease.

机构信息

National Key Discipline Laboratory, Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, PR China.

National Key Discipline Laboratory, Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, PR China.

出版信息

J Pharm Biomed Anal. 2021 Jun 5;200:114058. doi: 10.1016/j.jpba.2021.114058. Epub 2021 Apr 1.

DOI:10.1016/j.jpba.2021.114058
PMID:33865049
Abstract

AIMS

The aim of this study was to identify novel serum metabolites associated with non-alcoholic fatty liver disease (NAFLD), and to explore the metabolic discrepancies between Lean-NAFLD and Obese-NAFLD.

METHODS

Serum samples from patients with NAFLD (n = 161) and healthy participants (n = 149) were collected, and metabolites were analyzed with UPLC-Q-TOF MS/MS. Subgroup analyses were performed to explore the metabolic differences among Lean-NAFLD, Obese-NAFLD and healthy controls RESULTS: A total of 24 differentially present metabolites were found between patients with NAFLD and healthy controls. Marked metabolic pathway differences were observed among the NAFLD subtypes, including in fatty acid and amino acid metabolism. Ultimately, five metabolites (prasterone, indoxylsulfuric acid, sebacic acid, arachidonic acid and pregnenolone sulfate) were used to establish a diagnostic model to distinguish patients with NAFLD regardless of Lean- or Obese-NAFLD type.

CONCLUSIONS

This study suggested that significant metabolic differences existed among subtypes of NAFLD, and our model might be useful to distinguish patients with NAFLD. These findings may lay a foundation for the detection and treatment of NAFLD subtypes.

摘要

目的

本研究旨在鉴定与非酒精性脂肪性肝病(NAFLD)相关的新型血清代谢物,并探讨瘦型 NAFLD 和肥胖型 NAFLD 之间的代谢差异。

方法

收集 NAFLD 患者(n=161)和健康对照者(n=149)的血清样本,采用 UPLC-Q-TOF MS/MS 分析代谢物。进行亚组分析以探讨瘦型 NAFLD、肥胖型 NAFLD 和健康对照组之间的代谢差异。

结果

在 NAFLD 患者和健康对照者之间共发现 24 种差异表达的代谢物。在 NAFLD 亚型之间观察到明显的代谢途径差异,包括脂肪酸和氨基酸代谢。最终,使用 5 种代谢物(孕烯醇酮、吲哚硫酸、癸二酸、花生四烯酸和孕烷醇酮硫酸盐)建立了一个诊断模型,可用于区分无论瘦型或肥胖型 NAFLD 类型的患者。

结论

本研究表明,NAFLD 亚型之间存在显著的代谢差异,我们的模型可能有助于区分 NAFLD 患者。这些发现可能为 NAFLD 亚型的检测和治疗奠定基础。

相似文献

1
Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease.血清非靶向代谢组学描绘了不同非酒精性脂肪性肝病亚型的代谢状态。
J Pharm Biomed Anal. 2021 Jun 5;200:114058. doi: 10.1016/j.jpba.2021.114058. Epub 2021 Apr 1.
2
Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease.基于质谱的非酒精性脂肪性肝病非肥胖个体的非靶向代谢组学研究
Scand J Gastroenterol. 2023 Jul-Dec;58(11):1344-1350. doi: 10.1080/00365521.2023.2225667. Epub 2023 Jun 20.
3
Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children.整合代谢组学强调肠道微生物群代谢物作为儿童非酒精性脂肪性肝病相关的新型候选生物标志物。
Microbiol Spectr. 2024 Apr 2;12(4):e0523022. doi: 10.1128/spectrum.05230-22. Epub 2024 Mar 6.
4
A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.采用代谢组学方法验证非酒精性脂肪性肝病中的预测代谢物和表型表达。
Life Sci. 2023 Jun 1;322:121626. doi: 10.1016/j.lfs.2023.121626. Epub 2023 Mar 31.
5
New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model.利用小鼠模型分析肠道菌群和代谢物对非肥胖性非酒精性脂肪性肝病的新特征。
mSystems. 2024 Mar 19;9(3):e0102723. doi: 10.1128/msystems.01027-23. Epub 2024 Feb 29.
6
Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.尿液代谢组学分析确定了非酒精性脂肪性肝病不同阶段的关键生物标志物。
World J Gastroenterol. 2017 Apr 21;23(15):2771-2784. doi: 10.3748/wjg.v23.i15.2771.
7
Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.肥胖患者中非酒精性脂肪肝的临床和代谢特征:一种靶向代谢组学方法。
Diabetes Metab. 2019 Apr;45(2):132-139. doi: 10.1016/j.diabet.2018.09.003. Epub 2018 Sep 26.
8
Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry.使用液相色谱 - 质谱联用技术对人类早期非酒精性脂肪性肝病进行代谢分析。
J Transl Med. 2021 Apr 15;19(1):152. doi: 10.1186/s12967-021-02820-7.
9
Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.基于质谱分析的高脂饮食诱导的C57BL/6J小鼠非酒精性脂肪性肝病发展模型的血清代谢组学研究
J Agric Food Chem. 2015 Sep 9;63(35):7873-84. doi: 10.1021/acs.jafc.5b02830. Epub 2015 Aug 27.
10
Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study.非酒精性脂肪性肝病青少年的氨基酸代谢改变——一项非靶向、高分辨率代谢组学研究
J Pediatr. 2016 May;172:14-19.e5. doi: 10.1016/j.jpeds.2016.01.026. Epub 2016 Feb 5.

引用本文的文献

1
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
2
Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD.循环代谢物特征表明,在瘦型和肥胖型代谢相关脂肪性肝病中,肠道与肝脏之间存在不同的相互作用。
JCI Insight. 2025 Mar 18;10(8). doi: 10.1172/jci.insight.180943. eCollection 2025 Apr 22.
3
Metabolomics at the cutting edge of risk prediction of MASLD.
代谢组学处于非酒精性脂肪性肝病(MASLD)风险预测的前沿。
Cell Rep Med. 2024 Dec 17;5(12):101853. doi: 10.1016/j.xcrm.2024.101853. Epub 2024 Dec 9.
4
Medium-chain dicarboxylic acids: chemistry, pharmacological properties, and applications in modern pharmaceutical and cosmetics industries.中链二羧酸:化学、药理特性及其在现代制药和化妆品行业中的应用。
RSC Adv. 2024 May 28;14(24):17008-17021. doi: 10.1039/d4ra02598a. eCollection 2024 May 22.
5
Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine.代谢组学在非酒精性脂肪性肝病诊断及中医药治疗中的应用
Front Pharmacol. 2022 Aug 25;13:971561. doi: 10.3389/fphar.2022.971561. eCollection 2022.
6
Evaluation of Untargeted Metabolomic Strategy for the Discovery of Biomarker of Breast Cancer.用于发现乳腺癌生物标志物的非靶向代谢组学策略评估
Front Pharmacol. 2022 May 30;13:894099. doi: 10.3389/fphar.2022.894099. eCollection 2022.
7
Vancomycin-Induced Modulation of Gram-Positive Gut Bacteria and Metabolites Remediates Insulin Resistance in iNOS Knockout Mice.万古霉素诱导的革兰氏阳性肠道细菌和代谢物的调节可改善 iNOS 敲除小鼠的胰岛素抵抗。
Front Cell Infect Microbiol. 2022 Jan 19;11:795333. doi: 10.3389/fcimb.2021.795333. eCollection 2021.
8
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.硝态氮、二甲双胍、吡格列酮以及氨苄青霉素和新霉素联合处理对 iNOS 基因敲除小鼠胰岛素抵抗、血脂异常及血清代谢组的调控作用
Int J Mol Sci. 2021 Dec 24;23(1):195. doi: 10.3390/ijms23010195.